一种瘤条件的IL-15安全地与免疫疗法协同作用,以增强抗瘤免疫反应
Wenqiang Shi1, Wei Xu2, Luyao Song1
1Engineering Research Center of Cell and Therapeutic Antibody, Ministry of Education, School of Pharmacy, Shanghai Jiao Tong University, 800 Dongchuan Road, Shanghai 200240, China; Shanghai Frontiers Science Center for Drug Target Identification and Delivery, National Key Laboratory of Innovative Immunotherapy, School of Pharmacy, Shanghai Jiao Tong University, 800 Dongchuan Road, Shanghai 200240, China.
一种新型瘤条件的Interleukin-15 (亲IL-15) 疗法有效地增强了抗癌T细胞的毒性. 这种方法克服了对免疫疗法的耐药性,并显示出对治疗固体瘤的希望.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 生物技术是生物技术.
背景情况:
- 癌症免疫疗法面临着与免疫相关的不良事件和耐药性的挑战.
- 介素-15 (IL-15) 增强T细胞反应,但受到毒性限制.
- 开发有针对性的疗法来激活瘤透淋巴细胞至关重要.
研究的目的:
- 开发一种瘤条件的IL-15 (亲IL-15),以增强抗瘤免疫力,同时最大限度地降低全身毒性.
- 评估pro-IL-15在克服抗癌免疫疗法的疗效.
- 评估pro-IL-15与其他免疫疗法结合的潜力.
主要方法:
- 设计了一种由Fc片段和IL-15Rα-sushi域掩盖的亲IL-15结构,用于瘤特定激活.
- 系统地给予pro-IL-15并评估其对T细胞扩张,激活和耗尽的影响.
- 在固体瘤模型中评估了亲IL-15的疗效,包括组合疗法.
主要成果:
- 与传统IL-15相比,Pro-IL-15表现出强大的抗瘤活性,毒性显著降低.
- 亲IL-15活化了耗尽的CD8+T细胞,并增强了检查点阻塞疗法的疗效.
- 与亲IL-15的联合治疗改善了CD8/Treg比率和干扰素-γ水平,导致感冒瘤的回归.
结论:
- 益尔-IL-15是一种有前途的策略,用于强效的癌症免疫疗法,具有更好的安全性.
- 这种方法有效地克服了对当前免疫疗法的耐药性,并显示了长期治愈的潜力.
- Pro-IL-15为对抗固体瘤的联合疗法提供了一个多功能平台.
更多相关视频
07:55Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
07:20Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation
Published on: January 14, 2011
相关概念视频
Tumor Immunotherapy
The Tumor Microenvironment
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against...
